Management of mixed arterial and venous leg ulcers  by Humphreys, M.L. et al.
Abstracts
Gregory L. Moneta, MD, Abstracts Section EditorManagement of mixed arterial and venous leg ulcers
Humphreys ML, Stewart AR, Gohel MS, et al. Brit J Surg 2007;94:1104-7.
Conclusion:Good healing rates can be obtained for ulcerated extrem-
ities with combined arterial and venous disease using a protocol of selective
revascularization combined with supervised moderate compression.
Summary: During a 6-year period, 2011 ulcerated legs were seen in a
specialized leg ulcer clinic. Of these extremities, 1416 (70.4%) had venous
reflux. Legs without arterial disease, defined as an ankle-brachial index (ABI)
0.85, were treated with multilayer compression bandages. Patients with
severe arterial disease, defined as an ABI 0.5, were considered for urgent
revascularization. Those with moderate ischemia (ABI 0.5 to 0.85) underwent
supervised moderate compression and revascularization if their ulcer did not
heal. Healing rates for each group were determined using life-table analysis.
Of the 1416 patients with venous reflux, arterial disease was moderate
in 193 (13.6%) and severe in 31 (2.2%). At 36 weeks, healing rates for legs
with insignificant, moderate, and severe arterial disease were 87%, 68% and
53%, respectively (P  .001). There were 32 legs that were revascularized;
arterial disease was moderate in 17 and severe in 15. Healing occurred36
weeks in four of the 17 legs with moderate disease and in seven of the 15 legs
with severe arterial disease (P  .270). The 30-day mortality for revascular-
ization was 6.5%.
Comment: The study indicates that in patients with mixed arterial
and venous ulcers who have moderate arterial disease, reasonable healing
rates can be achieved without revascularization of the extremity. The healing
rates in the revascularized extremities certainly were not so impressive that
this data can be used to justify a policy of aggressive revascularization in patients
with ulcers and combined venous and moderate arterial disease. A trial of
conservative management using modified compressive therapy seems reason-
able in patients with ulcers and moderate arterial disease and venous ulcer.
Degree of fusiform dilatation of the proximal descending aorta in type
B acute aortic dissection can predict late aortic events
Marui A, Mochizuki T, Koyama T, et al. J Thorac Cardiovasc Surg 2007;
134:1163-70.
Conclusion: Aortic diameter, a patent false lumen, and fusiform dila-
tation of the proximal descending aorta predict late aortic events in patients
with acute type B aortic dissection.
Summary: Most type B aortic dissections can be acutely managed
medically. Some, however, eventually require surgical intervention. There is
current intense interest in trying to predict which patients with acute type B
dissection will require intervention, with the thought that perhaps such
patients should be treated early with stent graft repair of their dissection. In
this study, the authors investigated whether an index that expresses the
degree of fusiform dilatation of the proximal descending aorta can predict
late aortic events in patients with acute type B aortic dissection.
A retrospective analysis was done of 141 patients with acute type B
dissection, without initial complications, to determine predictors of late aortic
events. Aortic events were defined as aortic dilatation, rupture, organ ischemia,
rapid enlargement of ulcer-like lesions, and refractory pain. An aortic fusiform
dilatation index was calculated using the formula: (maximum diameter of the
proximal descending aorta/the diameter of the distal aortic arch)  the diam-
eter of the descending aorta at the level of the pulmonary artery.
In patients with late aortic events, the fusiform index was 0.59 vs 0.53
in patients without late aortic events (P  .01). Most patients with a higher
fusiform index exhibited aortic dilatation earlier than those with a lower
fusiform index. By multivariate analysis, independent risk factors of aortic
events were a maximum aortic diameter 40 mm, a fusiform index 0.64,
and a patent false lumen, with hazard ratios of 3.18, 2.73, and 2.64,
respectively. For patients with all three predictors, the values of actuarial
freedom from aortic events at 1, 5, and 10 years were 22%, 17%, and 8%,
respectively. In patients with none of these predictors, actuarial freedom
from aortic events was 97%, 94%, and 90% at 1, 5, and 10, years.
Comment: This is another of a number of recent articles trying to predict
which patients with type B aortic dissection are most likely to require surgical
intervention. It is very clear that most patients with type B aortic dissection are
well managed medically. These data should be of interest to those planning
intervention trials for acute type B aortic dissection. A positive result favoring
intervention is more likely if the correct patients are studied.Small is beautiful: Why profundaplasty should not be forgotten
Savolainen H, Hansen A, Diehm N, et al. World J Surg 2007;31:2048-61.
Conclusion: Profundaplasty is a valuable option in claudication pa-
tients with superficial femoral artery occlusion and occlusive disease of the
common femoral and profunda femoris arteries. It is not useful in patients
with tissue loss.
Summary: The authors sought to evaluate the utility of profundaplasty
in themodernmanagement of vascular surgical patients. From January 2000
through December 2003, 97 patients (106 legs) underwent profundoplasty
at the authors’ institution in Switzerland. The superficial femoral artery was
occluded in 55 legs, and these patients (75%men) were included in the analysis.
Their mean age was 71 years and 35% had diabetes. The indication for pro-
fundaplasty was claudication in 29 (52%) and critical leg ischemia (CLI) in 26
(47%), either with rest pain in 17 (31%) or ulcers/gangrene in 9 (16%).
The operation used standard endarterectomy techniques with a bovine
pericardium patch. Mean follow-up was 33 months. The mean preoperative
ankle-branchial index (ABI) was 0.6. Clinical efficacy was defined as an
increase of one or more Rutherford categories without repeat limb revascu-
larization or amputation. Mortality and other morbidity were also analyzed.
The postoperative ABI significantly improved, as defined by an increase
of0.15, in 24 (44%) of the patients. Cumulative clinical success, as defined
above, was 80% at 3 years. Patients with claudication had better outcomes
than those with CLI (P  .04). Two minor amputations and two major
amputations were performed, all in patients with CLI. No ulcer healing
occurred in the nine patients with ulcers.
Comment: The study obviously has some significant drawbacks in that
the benefit in the patients with claudication was not defined by any func-
tional assessment. In the days of endovascular recanalization of the superfi-
cial femoral artery, it is doubtful isolated profundaplasty will be performed
very often for claudication. Perhaps the most important message here is to
reiterate that profundaplasty alone is seldom going to be adequate therapy
for CLI associated with tissue loss.
Glycemic control, lipid-lowering treatment, and prognosis in diabetic
patients with peripheral atherosclerotic disease
Feringa HH, Karagiannis FE, Vidakovic R, et al. Ann Vasc Surg 2007;21:
780-9.
Conclusion: Serial hemoglobin (Hb) A1C measurements improve risk
stratification in patients with peripheral arterial disease (PAD) and diabetes.
Desirable glycemic control is associated with statin therapy. Statin therapy is
also associated with improved long-term outcome.
Summary: Intensive blood glucose control in patients with diabetes
attenuates many complications associated with dysglycemia. Glycosylated
HbA1C measurements reflect long-term glucose control and may improve
risk stratification for patients with PAD and diabetes. The authors sought to
determine prognostic values of repeated HbA1C measurements, ankle-
brachial index (ABI) values, and if the use of long-term statins was associated
with improved glycemic control and outcome.
This was an observational cohort study of 525 consecutive diabetic
patients with PAD. Serial HbA1C levels and ABI values were obtained. Use
of long-term statin therapy was also determined. Median follow-up was 7
years. All-cause mortality was 37%, and cardiac death occurred in 22%. Both
decreases in HbA1C and HbA1C variability independently predicted out-
come. Decreases in ABI also predicted outcome. Patients receiving long-
term statin therapy were more likely to have decreased HbA1C values
(hazard ratio [HR], 1.86, 95% confidence interval [CI], 1.27-2.74) and
HbA1C values 7% (HR, 2.58; 95% CI, 1.49-4.48). Long-term statin use
was also associated with lower all-cause mortality (HR, 0.39; 95% CI,
0.26-0.61) and was significantly associated with a decreased risk of cardiac
death (HR, 0.040; 95% CI, 0.24-0.76).
Comment: This study adds to several others in the literature that
suggest beneficial features of statins regarding insulin secretion, insulin
sensitivity, and insulin-mediated glucose uptake in both patients with and
without diabetes (Am J Card 2006;98:66-69 and Atherosclerosis 2000;
150:121-127). Improved glycemic control may be one of the pleiotropic
affects of statins that benefit patients with PAD independent of cholesterol
level.1119
